Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model.
We investigated the effect of topical temporin A in the management of methicillin-resistant strain of Staphylococcus aureus (MRSA)-infected experimental surgical wounds in mice. The wound, cut through the panniculus carnosus of BALB/c mice, was inoculated with 5x10(7) colony-forming units of MRSA. Mice were treated with Allevyn, temporin A-soaked Allevyn, Allevyn and daily intraperitoneal teicoplanin (7mg/kg), temporin A-soaked Allevyn and daily intraperitoneal teicoplanin. Main outcome measurements were: quantitative bacterial culture, histological examination with assessment of micro-vessel density and of vascular endothelial growth factor (VEGF) expression in tissue sections, and VEGF plasma levels alike. Treatment with temporin-A associated with teicoplanin injection significantly reduced bacterial load to 0.85 x 10(1)+/-0.1 x 10(1)CFU/ml. Histological examination showed that infected mice receiving temporin A-soaked Allevyn (with or without teicoplanin) had a higher degree of granulation tissue formation and collagen deposition compared to the other treated groups. A significant increase in serum VEGF expression was observed in mice receiving temporin A topically and temporin A topically associated with intraperitoneal teicoplanin. In conclusion our results demonstrated that temporin A is effective in the management of infected wounds, by a significant bacterial growth inhibition and acceleration of wound repair process.
Simonetti
Oriana
O
Dermatological Clinic, Università Politecnica delle Marche, Ancona, Italy. o.simonetti@univpm.it
Cirioni
Oscar
O
Goteri
Gaia
G
Ghiselli
Roberto
R
Kamysz
Wojciech
W
Kamysz
Elzbieta
E
Silvestri
Carmela
C
Orlando
Fiorenza
F
Barucca
Claudia
C
Scalise
Alessandro
A
Saba
Vittorio
V
Scalise
Giorgio
G
Giacometti
Andrea
A
Offidani
Annamaria
A
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides; D008297:Male; D016106:Methicillin Resistance; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D009389:Neovascularization, Pathologic; D011506:Proteins / Q000494:pharmacology*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects*; D014946:Wound Infection / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D011506:Proteins; D042461:Vascular Endothelial Growth Factor A; C104501:temporin